Skip to Main Content

Author Details

Oscar Krijgsman
The Netherlands Cancer Institute
2008
66
30
PMIDPaper TitleJournal TitlePublished Year
38088895A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics.Clin Cancer Res2024
38054839Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.Cancer Res Commun2024
36545919MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance.Melanoma Res2023
36750559Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.Nat Commun2023
36812891An adverse tumor-protective effect of IDO1 inhibition.Cell Rep Med2023
34930786Plasticity of Extrachromosomal and Intrachromosomal BRAF Amplifications in Overcoming Targeted Therapy Dosage Challenges.Cancer Discov2022
35395848Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.Nat Commun2022
34230026Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.Clin Cancer Res2021
33558721Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.Nat Med2021
33531370Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.Cancer Res2021
33660299High CD8<sup>+</sup> tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy.Histopathology2021
34937871Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.Nat Commun2021
34296746Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma.Dis Model Mech2021
32271879Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.J Exp Med2020
31978349Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.Cell2020
31942075B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020
33262254Comprehensive analysis of cutaneous and uveal melanoma liver metastases.J Immunother Cancer2020
32770055Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.Nat Commun2020
32620126Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.J Transl Med2020
32187553FGFR1 Oncogenic Activation Reveals an Alternative Cell of Origin of SCLC in Rb1/p53 Mice.Cell Rep2020
30674724Frequent clonal relations between metastases and non-index prostate cancer lesions.JCI Insight2019
31743370Correction: Clonality analysis of pulmonary tumors by genome-wide copy number profiling.PLoS One2019
31303383Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.Cell2019
31577944Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy.Cell Rep2019
31618260Clonality analysis of pulmonary tumors by genome-wide copy number profiling.PLoS One2019
31160251Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.Lancet Oncol2019
31125352Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.PLoS One2019
31160710Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.Nat Cell Biol2019
29334371Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.Nat Med2018
30464211Integrative epigenetic taxonomy of primary prostate cancer.Nat Commun2018
30297911Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.Nat Med2018
30286710XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.BMC Bioinformatics2018
29507054Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.Mol Syst Biol2018
26918338miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110.Oncotarget2016
27729614Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.Oncotarget2016
27320919BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.Cell Rep2016
27373156Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.Cell Rep2016
27129152Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.Oncotarget2016
26993771Immortalization capacity of HPV types is inversely related to chromosomal instability.Oncotarget2016
26999069MITF: More Interesting Traits, Folks!Pigment Cell Melanoma Res2016
25515853Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Pigment Cell Melanoma Res2015
26460009Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.Proc Natl Acad Sci U S A2015
26375816High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.PLoS One2015
26105199Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.EMBO Mol Med2015
25887352CopywriteR: DNA copy number detection from off-target sequence data.Genome Biol2015
25825120Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.Mol Oncol2015
25668003Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.Br J Cancer2015
24478024Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.Genes Chromosomes Cancer2014
25502142Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.Nat Commun2014
25456132Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.Cell Rep2014
  • 1 - 50 of 66

Recommended Authors

Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 1
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 1
Chen Wang
College of Life Sciences, Sichuan University
Career Start Year 2013
Number of shared co-authors 4
Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 1
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 7
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 5
Charlotte K Y Ng
University of Bern
Career Start Year 2009
Number of shared co-authors 4
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 2
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 1
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 4
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 5
Bin Feng
The First Affiliated Hospital of Jinan University
Career Start Year 2004
Number of shared co-authors 3
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 3
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 9
Peter Van Loo
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 7
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 8
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 6
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 5
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 2
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 0
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Career Start Year 2000
Number of shared co-authors 15
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 0
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 8
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 9
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 8
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 1
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 9
Matthew Meyerson
Broad Institute
Career Start Year 1983
Number of shared co-authors 14

Collaborators

Daniel S Peeper
Netherlands Cancer Institute
Co-authored papers 36
Bauke Ylstra
Cancer Center Amsterdam, Vrije Universiteit Amsterdam
Co-authored papers 18
Gerrit A Meijer
The Netherlands Cancer Institute
Co-authored papers 13
Kristel Kemper
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 11
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Co-authored papers 6
David J Adams
Wellcome Sanger Institute
Co-authored papers 6
Emile E Voest
The Netherlands Cancer Institute
Co-authored papers 4
Mark A van de Wiel
Amsterdam University Medical Centers (Amsterdam UMC)
Co-authored papers 4
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 4
Richard A Scolyer
Co-authored papers 3
Georgina V Long
Co-authored papers 3
Ultan McDermott
Wellcome Sanger Institute
Co-authored papers 3
Eric J T Belt
Albert Schweitzer Hospital
Co-authored papers 2
Edwin Cuppen
Hartwig Medical Foundation
Co-authored papers 2
Remond J A Fijneman
The Netherlands Cancer Institute
Co-authored papers 2
Martijn P Lolkema
Erasmus MC Cancer Institute
Co-authored papers 2
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Co-authored papers 2
Tesa M Severson
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 2
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Co-authored papers 2
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Co-authored papers 2
Jonathan C Schisler
Co-authored papers 1
Peter J Oefner
Institute of Functional Genomics, University of Regensburg
Co-authored papers 1
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 1
Thomas Wurdinger
Co-authored papers 1
Johanna Ten Hoeve
California Nanosystems Institute, University of California los angeles
Co-authored papers 1
Denise M Wolf
University of California San Francisco
Co-authored papers 1
Gabriel Karin
David Geffen School of Medicine, University of California los angeles
Co-authored papers 1
Oscar M Rueda
University of Cambridge
Co-authored papers 1
Vineet Bafna
University of California San Diego
Co-authored papers 1
Marc van de Wetering
Princess Maxima Center for Pediatric Oncology
Co-authored papers 1
Release 1.2